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Conclusion: PlasmaBlade for ITA harvesting is superior to conventional electrocauter, demonstrating a better wall 
integrity, intact endothel and lower adventitial hemorrhage. Further investigations regarding more histological samples and 
the final cardiac computed-tomographies in all 20 patients remain to be carried out till May 2014. 
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Introduction: New generation drug-eluting stents (DES) have been shown to reduce stent thrombosis in randomized 
controlled trials compared with early generation DES. Data on the incidence of stent thrombosis in unselected patient 
cohorts undergoing new generation DES implantation remain scarce. 
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Method: Between March 2009 and December 2010, 2,537 unselected patients with coronary artery disease (CAD) 
received new generation DES and were prospectively followed for one year. Patients received dual antiplatelet therapy 
including aspirin and clopidogrel for one year, with the exception of STEMI patients treated from September 2009 
onwards, in whom prasugrel was used. A total of 1,250 (49%) presented with stable CAD, 705 (28%) with NSTE-ACS and 
582 (23%) patients with STEMI. The type of DES used were Biolimus-eluting stents (25%), Everolimus-eluting stents 
(49%), Zotarolimus-eluting stents (22%) and other new generation DES (4%). 
Results: The cumulative incidence of definite ST at 1 year amounted to 0.9%. A landmark analysis at 30 days revealed 
an incidence of ST of 0.2% after 30 days. There were significant differences in ST rates at one year stratified according to 
the clinical indications stable CAD, NSTEMI and STEMI (0.5% vs. 0.9% vs. 1.9%, overall p=0.03). 
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Conclusion: In a large cohort of unselected CAD patient treated with new generation DES at a tertiary center, the 
incidence of ST was low, albeit somewhat higher than published in randomized controlled trials. The incidence of stent 
thrombosis beyond 30 days has become exceedingly low. The population at highest risk for ST are STEMI patients. 
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Introduction: Coronary artery disease (CAD) is the health condition with the highest morbidity and mortality, as well as 
assumably with the highest economic burden in developed countries. Cost-estimations for patients with CAD and acute 
coronary syndromes (ACS) in Switzerland have been published, but not for the cohort of patients with stable CAD 
undergoing elective percutaneous coronary interventions (PCI) in general and in the Swiss-DRG environment in specific. 
Aim of the study was to close this gap. 
Method: To determine health care costs from a third party payer perspective, we calculated the hospital reimbursements 
as defined by Swiss-DRG v 1.0 for patients with stable CAD undergoing in-hospital PCI. The number of procedures, as 
well as the proportion of drug-eluting (DES) and bare-metal stents (BMS) were taken from the Swiss PCI annual statistics 
report 2012. Per patient case-weight (CW) determinants were length of hospital-stay (LOS), number of stents placed and 
intervention involving a bifurcation, respectively. Their distribution was derived from the BASKET-PROVE-cohort of Swiss 
patients with stable CAD and a LOS between 1 and 3 days. To get the overall costs the resulting case-mix (CM) was then 
multiplied with a PCI-weighted base-rate, which took into account the intercantonal differences. 
  
